Abstract
Patients with chronic hepatitis C virus infection (HCV) and decompensated liver disease are not uncommon and present a considerable therapeutic challenge. Interferon-alfa-based regimens, standard therapy for HCV until recently, are plagued by worse tolerability and efficacy in patients with decompensated disease than others. Recent data have emerged with direct-acting anti-viral agents (DAAs) that are currently available including sofosbuvir, ledipasvir, and ribavirin; sofosbuvir, daclatasvir +/− ribavirin; and sofosbuvir, simeprevir +/− ribavirin that reveal excellent tolerability and efficacy in this patient population. In fact, sofosbuvir, ledipasvir, and ribavirin demonstrated sustained virologic response (SVR) rates of 87 and 89 % in CTP B and C patients, respectively, with a 12-week course. The current HCV guidance document from the AASLD/IDSA addresses treatment regimen recommendations for patients with decompensated disease. Ongoing long-term studies that assess quality of life, effect on the complications of ESLD, the rates of de-listing for liver transplantation, rates of development of hepatocellular carcinoma, and mortality after SVR in patients with decompensated disease will help address the question of who to treat when. Data should be forthcoming, including data on emerging therapies. The decision to treat patients with decompensated disease may be difficult, and such patients present complex clinical issues that dictate that experienced personnel administer therapy if at all possible.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol. 2000;32:673–84.
Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology. 1999;29:250–6.
Sanchez-Fueyo A, Restrepo JC, Quinto L, Brueguera M, Grande L, Sanchez-Tapias JM, et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation. 2002;73:56–63.
Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol. 2012;57:442–50.
Kim WR, Terrault NA, Pedersen RA, Therneau TM, Edwards E, Hindman AA, et al. Trends in waiting list registration for liver transplantation for viral hepatitis in the United States. Gastroenterology. 2009;137:1680–6.
Forns X, Garcia-Retrotillo M, Serrano T, Feliu A, Suarez F, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol. 2003;39:389–96.
Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology. 2005;42:255–62.
Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl. 2002;8:350–5.
Iacobellis A, Siciliano M, Perri F, Annicchiarico B, Leandro G, et al. Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study. J Hepatol. 2007;46:206–12.
Kwo PY, Mantry PS, Coakley E, Te H, et al. An interferon-free antiviral regimen for HCV after liver transplantation. NEJM. 2014;371:2375–82. First report of treatment of post- trasnplantation patients with HCV with well tolerated, highly efficacious DAAs.
The American Association for the Study of Liver Diseases. Recommendations for Testing, Managing, and Treating Hepatitis C.. Accessed 10 September 2015. Available from: URL: http://www.hcvguidelines.org/. HCV Guidance document that is frequently updated and provides timely recommendations for testing, management and treatment of HCV in a rapidly changing field.
Gambato M, Lens S, Navasa M, Forns X. Treatment options in patients with decompensated cirrhosis, pre- and post- transplantation. J Hepatol. 2004;61:S120–31.
Crespo G, Marino Z, Navasa M, Forns X. Viral hepatitis in liver transplantation. Gastroenterology. 2012;142:1373–83.
Carrion JA, Martinez-Bauer E, Crespo G, Ramirez S, et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol. 2009;50:719–28.
Everson GT, Terrault NA, Lok AS, Rodrigo DR, Brown Jr RS, Saab S, et al. A randomized controlled trial of pre-transplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. Hepatology. 2013;57:1752–62.
Poordad F, McCone Jr J, Bacon BR, Bruno S, Manns MP, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1195–206.
Jacobson IM, McHutchison JG, Dusheiko G, Bisceglie AM, Reddy KR, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011;364:2405–16.
Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med. 2011;365:1014–24.
Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med. 2011;364:1207–17.
Hezode C, Fontaine H, Dorival C, Zoulim F, Larrey D, et al. Effectiveness of telaprevir or boceprevir in treament- experienced patients with HCV genotype 1 infection and cirrhosis. Gastroenterology. 2014;147:132–42.
Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–74.
Charlton M, Everson GT, Flamm SL, Kumar P, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149:649–59. First report of treatment of HCV patients with decompensated liver disease showing excellent tolerability and efficacy.
Manns M, Forns X, Samuel D, Denning J, Arterburn S, et al. Ledipasvir/sofosbuvir with ribavirin is safe and efficacious in decompensated and post liver transplantation patients with HCV infection: preliminary results of the prospective Solar 2 trial. J Hepatol. 2015;62:S187–8.
Curry M, O’Leary J, Bzowej N, Muir A, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2616–28. Emerging therapeutic regimen that showed excellent tolerability and efficacy in HCV patients with decompensated liver disease.
Poordad F, Schiff ER, Vierling JM, Landi C, Fontana RJ, et al. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or posttransplant recurrence: Phase 3 ALLY-1 study. J Hepatol. 2015; AL08.
Foster GR, McLauchlan J, Irving W, Cheung M, Hudson B, et al. Treatment of decompensated HCV cirrhosis in patients with diverse genotypes: 12 weeks sofosbuvir and NS5A inhibitors with/without ribavirin is effective in HCV genotypes 1 and 3. J Hepatol. 2015;63(4):A0002.
Welzel TM, Herzer K, Ferenci P, Petersen J, Geshwantler M, et al. Daclatasvir plus sofosbuvir with or without ribavirin for the treatment of HCV in patients with severe liver disease: interim results of a multicenter compassionate use program. J Hepatol. 2015;63(4):AP0772.
Reddy R, Lim JK, Kuo A, Di Bisceglie AM, Vargas HE, Morelli G, et al. All oral HCV therapy is safe and effective in patients with decompensated cirrhosis: interim report from the HCV-target real world experience. J Hepatol. 2015;63(4):A007.
Jacobson IM, Poordad F, Firpi-Morell R, Everson GT, et al. Efficacy and safety of grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with Child–Pugh class B cirrhosis (C-Salt part A). J Hepatol. 2015;63(4):A0008.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Steven L. Flamm reports grants and personal fees from Gilead, Abbvie, BMS, and Merck.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Hepatitis C
Rights and permissions
About this article
Cite this article
Flamm, S.L. How to Treat Patients with Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis. Curr Hepatology Rep 15, 60–66 (2016). https://doi.org/10.1007/s11901-016-0291-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11901-016-0291-0